| Title |
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study
|
|---|---|
| Published in |
Lung Cancer (01695002), January 2019
|
| DOI | 10.1016/j.lungcan.2019.01.016 |
| Pubmed ID | |
| Authors |
Yi-Long Wu, Caicun Zhou, Shun Lu, Shukui Qin, Hongming Pan, Gang Wu, Ying Cheng, Xiaoqing Liu, Baohui Han, Yunzhong Zhu, Zhaoyang Zhong, Cheng Huang, Lei Chen, Houjie Liang, Enxiao Li, Guoliang Jiang |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 14% |
| Student > Ph. D. Student | 5 | 12% |
| Other | 4 | 9% |
| Student > Master | 3 | 7% |
| Student > Bachelor | 2 | 5% |
| Other | 9 | 21% |
| Unknown | 14 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Business, Management and Accounting | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Unspecified | 2 | 5% |
| Other | 7 | 16% |
| Unknown | 16 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2020.
All research outputs
#20,663,600
of 25,385,509 outputs
Outputs from Lung Cancer (01695002)
#2,391
of 3,036 outputs
Outputs of similar age
#340,064
of 446,772 outputs
Outputs of similar age from Lung Cancer (01695002)
#38
of 54 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,036 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,772 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.